Brief: Abionyx Confirms Breakthrough Therapy Status of CER-001 in Kidney Diseases

Abionyx Pharma SA

02/03/2021 06:43

March 2 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX ANNOUNCES POSITIVE CLINICAL RESULTS FROM CER-001
IN AN
ULTRARARE KIDNEY DISEASE PUBLISHED IN THE ANNALS OF INTERNAL
MEDICINE
    * SYSTEMIC MECHANISM OF ACTION OF CER-001
    * DEMONSTRATED EFFICACY IN RENAL AND OPHTHALMIC INDICATION
    * CONFIRMATION OF BREAKTHROUGH THERAPY STATUS OF CER-001 IN
KIDNEY
AND OPHTHALMIC DISEASES
    * CER-001 WAS COMPLETELY SAFE AND VERY WELL TOLERATED AT
DOSES OF
10-30 MG/KG/WEEK

Source text for Eikon:  ID:nBw5CF34Ta 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))